Standard Biotools (LAB) Operating Leases (2019 - 2026)

Standard Biotools (LAB) has 8 years of Operating Leases data on file, last reported at $23.7 million in Q1 2026.

• Quarterly Operating Leases fell 5.0% year-over-year to $23.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.7 million (down 5.0% YoY) and the FY2025 annual result came in at $25.0 million, down 2.16% from the prior year.
• Operating Leases slipped to $23.7 million in Q1 2026 per LAB's latest filing, from $25.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $40.0 million in Q1 2022 and bottomed at $22.0 million in Q3 2025.
• The 5-year median for Operating Leases is $30.4 million (2023), against an average of $30.1 million.
• The widest annual swing landed in 2022, when Operating Leases fell 0.09%; it then decreased 21.9% in 2025.
• Tracing LAB's Operating Leases over 5 years: stood at $34.1 million in 2022, then slipped by 10.88% to $30.4 million in 2023, then fell by 15.75% to $25.6 million in 2024, then dropped by 2.16% to $25.0 million in 2025, then dropped by 5.54% to $23.7 million in 2026.
• Per Business Quant, the three latest LAB Operating Leases figures stand at $23.7 million (Q1 2026), $25.0 million (Q4 2025), and $22.0 million (Q3 2025).

Peer Comparison